Matthias Bozza’s Post

£300m #Investment Vehicle for Innovation: The #UniversityofBristol, as part of the SETsquared partnership with five other universities, is collaborating with QantX to launch a £300m investment vehicle focused on supporting #science and #technology spin-outs in the #SouthWest. Global Challenges Focus: The initiative targets early-stage companies addressing global issues, such as #sustainability, #cleanenergy, and transformative #healthcare, with enhanced patient capital, expertise, and support. Proven Track Record of SETsquared: The partnership, with a combined £600m research portfolio, has already generated over 230 spin-outs. Boosting Regional Growth and Impact: Professor Guy Poppy highlighted that this initiative will accelerate the commercialisation of research, strengthening the region's global reputation in #entrepreneurship while driving economic growth and addressing global challenges. https://lnkd.in/giTjSgJb

How much weight should be placed on intellectual property protection for Medtech startups? While patents often serve as a cornerstone for many startups, David Beylik’s perspective might surprise you. In this clip, David Beylik says that IP isn't always the primary focus for them. Regulatory approval, clinical data, and manufacturing expertise often carry more weight in terms of a company’s defensibility and long-term success. So, does that mean IP isn’t important? Not exactly. While IP might not always be a deal-breaker or maker, there are times when it’s critical and can halt an investment in its tracks. In other words, while IP might not always be at the forefront of an investment decision, when it matters, it really matters. For innovators, this means that building a strong IP portfolio should be part of a broader strategy that includes securing regulatory approvals and developing robust operational capabilities. Tune into the full LSI USA ‘24 panel, “IP: Friend or Foe in Building Medtech Ventures?” to hear more from the panelists on this nuanced discussion. Hear from: • Irfan Lateef (Moderator) — Knobbe Martens • Leah Brownlee — Lazurite • Sabing Lee — Knobbe Martens • David Beylik — Ajax Health

In 2024, it's clear that funding for biotechs is at the core of the success that a drug can have. We've seen a surge in investment due to breakthrough research and urgent medical needs. The industry has pointed to a focus on sustainability and long-term impact. Investors now seek companies committed to tackling global challenges. This shift may prioritize projects offering more of a return on investment. US Biotech firms saw a 15% increase in venture funding year-over-year, according to PitchBook Data. This shows confidence in the sector. Startups must adapt by showcasing how their innovations drive long-term health benefits and returns. What trends are you seeing in biotech funding? Share your thoughts below.

Some good news from EIC for Lithuanian biotech innovators 🇱🇹🇪🇺 The EIC Work Programme 2025 launches a new funding opportunity: STEP Scale Up. This new initiative is designed to provide major support for companies developing critical technologies, helping them secure larger equity rounds and scale to new heights. Here’s why STEP Scale Up stands out: 💡 Targeting biotechnologies, deep-tech, and net-zero innovations. 💶Eligible companies can request €10mn - €30mn in funding, with a goal to catalyze €50mn - €150mn equity rounds. 📊 Companies need a pre-commitment for at least 20% of the target round from a qualified investor. 🧬 If you are driving game-changing innovation in biotech ir digital technologies, this could be your next big step 🚀 #Biotech #Innovation #EICScaling #ScaleUp #LithuanianBiotech #FundingOpportunities

We will be hosting our next #Investors + #Innovators meet up on 16 July in central #Bristol. The topic for this event will be #Biotech and #MedTech, and if you are an investor or innovator with an interest in these technologies, do sign up for this free networking event. Full details and registration via this link https://lnkd.in/eR-KUUtA #networking #lifesciences #innovation

We are bringing our Investors + Innovators meet up events to #Bristol. If you are an #investor or #innovator working in #biotech or #MedTech do come an join us for an evening of networking over drinks and pizza. Details in the post below. Angel Investors Bristol Louis Robertson Laura Wood Katie Burfitt Henrietta Brown Laurent Perge Stephen H. Charles Harrewyn UKBAA Ellen Green Daisy Eckett

As I prepare for the LSX World Congress this week and check the current MedTech market, it's great to see that 𝗖𝗮𝗹𝗶𝗳𝗼𝗿𝗻𝗶𝗮𝗻 𝘀𝘁𝗮𝗿𝘁𝘂𝗽𝘀 𝗮𝗿𝗲 𝗶𝗻 𝗮 "𝗵𝗼𝘁 𝘀𝗽𝗼𝘁" 𝗳𝗼𝗿 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗳𝘂𝗻𝗱𝗿𝗮𝗶𝘀𝗶𝗻𝗴. 2024 is showing robust financial engagement in the sector. This year, several medical device startups have secured significant funding, highlighting strong investor interest in innovative healthcare solutions. See: https://lnkd.in/gNpNNcqX, https://lnkd.in/gdy63Ctb Overall, the broader biotech investment landscape in 2024 presents a mixed but generally positive outlook. The industry has seen substantial global investment activity, with over 57,000 funding rounds completed, demonstrating the sector's ongoing growth. Source: https://lnkd.in/g3mrN2-k #Biotech #MedTech #Startup #Investments #LSX LSX World Congress Livivos, Inc

With today’s more stringent investor requirements in mind, it’s worth taking a look at a few of the stand-out Medtech investment deals completed thus far in 2024 to help identify common threads attracting investor interest. 𝐖𝐨𝐦𝐞𝐧’𝐬 𝐇𝐞𝐚𝐥𝐭𝐡, 𝐍𝐞𝐮𝐫𝐨𝐬𝐭𝐢𝐦, 𝐚𝐧𝐝 𝐈𝐧𝐜𝐨𝐧𝐭𝐢𝐧𝐞𝐧𝐜𝐞 𝐆𝐚𝐢𝐧 𝐄𝐚𝐫𝐥𝐲-𝐒𝐭𝐚𝐠𝐞 𝐃𝐨𝐥𝐥𝐚𝐫𝐬 Of the early-stage Medtech rounds completed in the first half of the year, UK-based Amber Therapeutics’ huge $100 million Series A haul, which closed in June, tops the list. The company garnered one of the largest Series A rounds ever for a European Medtech company. Although the deal seems massive for a little-known company founded only three years ago, it should not be surprising given Amber’s focus on neuromodulation (one of the hottest growth areas) and women’s health (one of the most underserved), as well as its quick, cash-sparing path to the clinic (the company was founded in 2021, began its first human study in late 2022, and by early 2024 had preliminary results confirming the safety and feasibility of its technology). The Series A raise was financed by a syndicate of US and UK investors led by…. Continue reading this article and explore the full first edition of The Lens for free on our site. Subscribe today to receive the upcoming December issue and all 12 editions in 2025: https://lnkd.in/dZEXphUB

Last night, the Technology Investment Network launched the third edition of the New Zealand Healthtech Report, quantifying the sector and its key markets, investment, and business spending. New Zealand’s health-tech export sector is shown to have more than doubled in the past decade, from $1.27B to $2.62B, and is the country’s second-largest tech vertical behind fintech. Total revenue grew 2.4% or $61m in 2023, below the sector’s five-year CAGR of 7.8%, reflecting a natural adjustment from COVID-level highs. ”With its compelling potential, health-tech is a sector our Aspire NZ Seed Fund (Aspire) continues to support, with impressive companies within our portfolio including (but not limited to) Aroa Biosurgery Limited, AVASA, Core Schedule , Formus Labs, Inhibit Coatings, InsituGen Ltd, JUNOFEM, Kitea Health, Orbis Diagnostics, The Clinician, The Insides Company, and Wellumio. However, current market conditions have meant that funding is harder to secure than in prior years and additional support remains necessary to ensure the sector’s continued growth” notes our Investment Manager, Byron van Vugt. Congratulations to Greg Shanahan, Alex Dickson and the team at TIN for producing yet another in-depth start-up sector report, we are proud to be supporting the work you do in this space. Check out the report here: https://lnkd.in/gyx_iUJ8 

🌟 🚀 Exciting news from the Center for Technology Transfer and Commercialization (CTTC)! We're honored to be featured in Vanderbilt's latest article, which highlights how we help bring medical breakthroughs from the lab to the market. A special mention to Alan Bentley, who was quoted in the piece. It’s inspiring to see how collaboration between academia and industry is driving innovation and making a real impact on healthcare. Check out the full article to learn more about what’s happening at Vanderbilt. https://lnkd.in/eQQxmPJR #Innovation #TechnologyTransfer #Vanderbilt #Entrepreneurship